Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Mesoblast LimitedNASDAQ: MESO

Gross Margin · Q4 FY2026 · quarter ended Jun 2026

Gross margin widens to 143.2%

Gross margin was 143.2% in Q4 FY2026, up 374.3 pp from a year earlier. On a trailing-twelve-month basis it was 80.0%, up 288.5 pp year over year. Over 3 fiscal years it widened by 716.3 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2026 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
143.2%+0.0 pp QoQ
Last fiscal yearJun 2026
84.1%+13.9 pp YoY
LTMJun 2026
80.0%+288.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+374.3 pp——
1 year+13.9 pp——
3 years+716.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2026
84.1%
Year-over-year change
+13.9pp

Gross Margin vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 gross margin of 80.0% is the 2nd highest of the 5 companies compared; the peer median is 66.5%.
  • Its year-over-year change of +288.5 pp is the highest of 5, against a peer median of +2.3 pp.
  • Over three fiscal years its change of +716.3 pp compares with a peer median of +7.7 pp.
MESO Competitors Peer median
Gross Margin for MESO and competitors
Company Period LTM level YoY 3-year change
LCTXLineage Cell Therapeutics, Inc.LTM Mar 202698.0% +0.8 pp-0.9 pp
MESOMesoblast LimitedLTM Jun 202680.0% +288.5 pp+716.3 pp
CELUCelularity Inc.LTM Dec 202576.0% +3.7 pp+85.4 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
CAPRCapricor Therapeutics, Inc.FY2025— ——
Peer median (excluding MESO) 66.5%+2.3 pp+7.7 pp

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue10.21M7.5M5.9M17.2M120.79M
Cost of Revenue63.57M54.92M41.07M5.13M19.21M
Gross Profit(53.36M)(47.42M)(35.17M)12.07M101.58M
Gross Margin-522.6%-632.2%-595.9%70.2%84.1%
Research & Development32.82M27.19M25.35M34.81M97.94M
Selling, General & Admin57.97M53.11M23.63M39.31M55.13M
Operating Expenses90.79M76.79M48.98M74.51M153.08M
Depreciation & Amortization4.38M4.11M1.9M6.4M8.62M
EBITDA(76.57M)(58.55M)(56.08M)(73.66M)(42.88M)
EBITDA Margin-749.9%-780.6%-950.1%-428.3%-35.5%
Operating Income(80.57M)(69.29M)(84.15M)(62.44M)(51.5M)
Operating Margin-789.1%-923.7%-1425.7%-363.1%-42.6%
Interest Income0831K1.82M3.55M3.93M
Interest Expense17.29M19.44M20.66M22.93M23.95M
Other Income / Expenses(10.48M)(12.81M)(4M)(39.37M)(5.64M)
Income Before Tax(91.59M)(82.1M)(88.15M)(101.81M)(57.14M)
Pre-Tax Margin-896.9%-1094.5%-1493.5%-592.0%-47.3%
Income Tax Expense(239K)(212K)(191K)330K615.74K
Net Income(91.35M)(81.89M)(87.96M)(102.14M)(57.76M)
Net Margin-894.6%-1091.7%-1490.3%-593.9%-47.8%
EPS (Basic)(1.30)(0.98)(0.89)(0.84)(0.45)
EPS (Diluted)(1.30)(0.98)(0.89)(0.84)(0.45)
Weighted Avg Shares68.27M83.77M98.67M120.78M129.49M
Weighted Avg Shares (Diluted)68.29M83.93M98.67M120.78M129.49M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.